Delhi-Based Jagsonpal Pharma to Acquire Group Pharmaceuticals' Wellness Portfolio for Up to Rs 46.7 Crore
New Delhi: Jagsonpal Pharmaceuticals has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals to acquire its wellness portfolio on a going-concern basis through a slump sale. The transaction is aimed at strengthening Jagsonpal's pharmaceutical portfolio and expanding its presence across complementary therapeutic segments, particularly women's healthcare.
The wellness portfolio of Group Pharmaceuticals recorded a turnover of Rs 24.6 crore during FY2025-26. Under the terms of the transaction, Jagsonpal will pay an initial consideration of Rs 23.7 crore at closing. An additional consideration of up to Rs 23 crore will be linked to the sales achieved during FY2027-28, taking the maximum total consideration to Rs 46.7 crore.
The transaction is expected to be completed on or before November 1, 2026, subject to fulfilment of the conditions precedent and other terms and conditions specified under the Business Transfer Agreement.
The acquisition will provide Jagsonpal with an established portfolio of wellness products and an existing market presence. Following completion of the transaction, the company plans to integrate the acquired portfolio with its existing commercial platform and capabilities. It also intends to leverage its distribution network to create operating synergies.
Commenting on the transaction, Manish Gupta, Managing Director, Jagsonpal Pharmaceuticals, stated that the acquisition marks another step in the company’s growth journey. According to Gupta, the transaction will strengthen Jagsonpal’s pharmaceutical portfolio and expand its presence across complementary therapeutic segments, especially women’s healthcare, while remaining consistent with the company’s asset-light and focused approach to growth.
Gupta added that Jagsonpal remains focused on pursuing opportunities that complement its existing capabilities and create sustainable, long-term value for its stakeholders.
Amrut Medhekar, Chief Operating Officer, Jagsonpal Pharmaceuticals, expressed that the company is pleased to welcome the acquired portfolio and the employees of the business into its organisation. He stated that Jagsonpal is committed to ensuring their smooth and seamless integration.
Medhekar added that the company expects the acquisition to support its next phase of growth through expansion of its field force, strengthening of its pan-India presence and creation of significant cross-selling opportunities across its portfolio. He said the company looks forward to a seamless transition and intends to leverage its established commercial infrastructure and execution capabilities to unlock the full growth potential of the acquired portfolio.
Jagsonpal Pharmaceuticals has an existing portfolio of drugs focused on gynaecology, orthopaedics, dermatology and child-care segments. The acquisition of the wellness portfolio is expected to add to the company's existing commercial portfolio and therapeutic presence.
Jagsonpal also reported growth in its financial performance for the quarter ended June 30, 2026 (Q1 FY27). The company recorded a 22.15% year-on-year increase in standalone net profit to Rs 13.18 crore, compared with Rs 10.79 crore in Q1 FY26. Revenue from operations increased 8.76% year-on-year to Rs 82.23 crore, compared with Rs 75.60 crore in the corresponding quarter of the previous financial year, reports Business Standard.
